Cardiometabolic Drug Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: C167D9010D47EN
Market Monitor Global

Abstracts

Cardiometabolic drugs are purposefully used for a vast composition of metabolic dysfunction, disorders include impaired glucose tolerance, insulin resistance, hypertension, dyslipidemia, and central adiposity.

This report contains market size and forecasts of Cardiometabolic Drug in Global, including the following market information:

Global Cardiometabolic Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cardiometabolic Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Impaired Glucose Tolerance Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cardiometabolic Drug include Gilead Sciences, AbbVie, Sanofi, InovoBiologic, Carmel Biosciences, Genfit, Kochi Prefecture and Besins Healthcare, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cardiometabolic Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cardiometabolic Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cardiometabolic Drug Market Segment Percentages, by Type, 2021 (%)

• Impaired Glucose Tolerance Drug
• Insulin Resistance Drug
• Hypertension Drug
• Dyslipidemia Drug
• Central Adiposity Drug

Global Cardiometabolic Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cardiometabolic Drug Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Online Pharnacies
• Retail Pharmacies

Global Cardiometabolic Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cardiometabolic Drug Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cardiometabolic Drug revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cardiometabolic Drug revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Gilead Sciences
• AbbVie
• Sanofi
• InovoBiologic
• Carmel Biosciences
• Genfit
• Kochi Prefecture
• Besins Healthcare

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cardiometabolic Drug Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cardiometabolic Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CARDIOMETABOLIC DRUG OVERALL MARKET SIZE

2.1 Global Cardiometabolic Drug Market Size: 2021 VS 2028
2.2 Global Cardiometabolic Drug Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cardiometabolic Drug Players in Global Market
3.2 Top Global Cardiometabolic Drug Companies Ranked by Revenue
3.3 Global Cardiometabolic Drug Revenue by Companies
3.4 Top 3 and Top 5 Cardiometabolic Drug Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cardiometabolic Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cardiometabolic Drug Players in Global Market
  3.6.1 List of Global Tier 1 Cardiometabolic Drug Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cardiometabolic Drug Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Cardiometabolic Drug Market Size Markets, 2021 & 2028
  4.1.2 Impaired Glucose Tolerance Drug
  4.1.3 Insulin Resistance Drug
  4.1.4 Hypertension Drug
  4.1.5 Dyslipidemia Drug
  4.1.6 Central Adiposity Drug
4.2 By Type - Global Cardiometabolic Drug Revenue & Forecasts
  4.2.1 By Type - Global Cardiometabolic Drug Revenue, 2017-2022
  4.2.2 By Type - Global Cardiometabolic Drug Revenue, 2023-2028
  4.2.3 By Type - Global Cardiometabolic Drug Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cardiometabolic Drug Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Online Pharnacies
  5.1.4 Retail Pharmacies
5.2 By Application - Global Cardiometabolic Drug Revenue & Forecasts
  5.2.1 By Application - Global Cardiometabolic Drug Revenue, 2017-2022
  5.2.2 By Application - Global Cardiometabolic Drug Revenue, 2023-2028
  5.2.3 By Application - Global Cardiometabolic Drug Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cardiometabolic Drug Market Size, 2021 & 2028
6.2 By Region - Global Cardiometabolic Drug Revenue & Forecasts
  6.2.1 By Region - Global Cardiometabolic Drug Revenue, 2017-2022
  6.2.2 By Region - Global Cardiometabolic Drug Revenue, 2023-2028
  6.2.3 By Region - Global Cardiometabolic Drug Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Cardiometabolic Drug Revenue, 2017-2028
  6.3.2 US Cardiometabolic Drug Market Size, 2017-2028
  6.3.3 Canada Cardiometabolic Drug Market Size, 2017-2028
  6.3.4 Mexico Cardiometabolic Drug Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Cardiometabolic Drug Revenue, 2017-2028
  6.4.2 Germany Cardiometabolic Drug Market Size, 2017-2028
  6.4.3 France Cardiometabolic Drug Market Size, 2017-2028
  6.4.4 U.K. Cardiometabolic Drug Market Size, 2017-2028
  6.4.5 Italy Cardiometabolic Drug Market Size, 2017-2028
  6.4.6 Russia Cardiometabolic Drug Market Size, 2017-2028
  6.4.7 Nordic Countries Cardiometabolic Drug Market Size, 2017-2028
  6.4.8 Benelux Cardiometabolic Drug Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Cardiometabolic Drug Revenue, 2017-2028
  6.5.2 China Cardiometabolic Drug Market Size, 2017-2028
  6.5.3 Japan Cardiometabolic Drug Market Size, 2017-2028
  6.5.4 South Korea Cardiometabolic Drug Market Size, 2017-2028
  6.5.5 Southeast Asia Cardiometabolic Drug Market Size, 2017-2028
  6.5.6 India Cardiometabolic Drug Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Cardiometabolic Drug Revenue, 2017-2028
  6.6.2 Brazil Cardiometabolic Drug Market Size, 2017-2028
  6.6.3 Argentina Cardiometabolic Drug Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cardiometabolic Drug Revenue, 2017-2028
  6.7.2 Turkey Cardiometabolic Drug Market Size, 2017-2028
  6.7.3 Israel Cardiometabolic Drug Market Size, 2017-2028
  6.7.4 Saudi Arabia Cardiometabolic Drug Market Size, 2017-2028
  6.7.5 UAE Cardiometabolic Drug Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Gilead Sciences
  7.1.1 Gilead Sciences Corporate Summary
  7.1.2 Gilead Sciences Business Overview
  7.1.3 Gilead Sciences Cardiometabolic Drug Major Product Offerings
  7.1.4 Gilead Sciences Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.1.5 Gilead Sciences Key News
7.2 AbbVie
  7.2.1 AbbVie Corporate Summary
  7.2.2 AbbVie Business Overview
  7.2.3 AbbVie Cardiometabolic Drug Major Product Offerings
  7.2.4 AbbVie Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.2.5 AbbVie Key News
7.3 Sanofi
  7.3.1 Sanofi Corporate Summary
  7.3.2 Sanofi Business Overview
  7.3.3 Sanofi Cardiometabolic Drug Major Product Offerings
  7.3.4 Sanofi Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.3.5 Sanofi Key News
7.4 InovoBiologic
  7.4.1 InovoBiologic Corporate Summary
  7.4.2 InovoBiologic Business Overview
  7.4.3 InovoBiologic Cardiometabolic Drug Major Product Offerings
  7.4.4 InovoBiologic Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.4.5 InovoBiologic Key News
7.5 Carmel Biosciences
  7.5.1 Carmel Biosciences Corporate Summary
  7.5.2 Carmel Biosciences Business Overview
  7.5.3 Carmel Biosciences Cardiometabolic Drug Major Product Offerings
  7.5.4 Carmel Biosciences Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.5.5 Carmel Biosciences Key News
7.6 Genfit
  7.6.1 Genfit Corporate Summary
  7.6.2 Genfit Business Overview
  7.6.3 Genfit Cardiometabolic Drug Major Product Offerings
  7.6.4 Genfit Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.6.5 Genfit Key News
7.7 Kochi Prefecture
  7.7.1 Kochi Prefecture Corporate Summary
  7.7.2 Kochi Prefecture Business Overview
  7.7.3 Kochi Prefecture Cardiometabolic Drug Major Product Offerings
  7.7.4 Kochi Prefecture Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.7.5 Kochi Prefecture Key News
7.8 Besins Healthcare
  7.8.1 Besins Healthcare Corporate Summary
  7.8.2 Besins Healthcare Business Overview
  7.8.3 Besins Healthcare Cardiometabolic Drug Major Product Offerings
  7.8.4 Besins Healthcare Cardiometabolic Drug Revenue in Global Market (2017-2022)
  7.8.5 Besins Healthcare Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cardiometabolic Drug Market Opportunities & Trends in Global Market
Table 2. Cardiometabolic Drug Market Drivers in Global Market
Table 3. Cardiometabolic Drug Market Restraints in Global Market
Table 4. Key Players of Cardiometabolic Drug in Global Market
Table 5. Top Cardiometabolic Drug Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cardiometabolic Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cardiometabolic Drug Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cardiometabolic Drug Product Type
Table 9. List of Global Tier 1 Cardiometabolic Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cardiometabolic Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cardiometabolic Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cardiometabolic Drug Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cardiometabolic Drug Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Cardiometabolic Drug Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cardiometabolic Drug Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cardiometabolic Drug Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Cardiometabolic Drug Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cardiometabolic Drug Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cardiometabolic Drug Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cardiometabolic Drug Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cardiometabolic Drug Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cardiometabolic Drug Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cardiometabolic Drug Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cardiometabolic Drug Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cardiometabolic Drug Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cardiometabolic Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cardiometabolic Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cardiometabolic Drug Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cardiometabolic Drug Revenue, (US$, Mn), 2023-2028
Table 30. Gilead Sciences Corporate Summary
Table 31. Gilead Sciences Cardiometabolic Drug Product Offerings
Table 32. Gilead Sciences Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 33. AbbVie Corporate Summary
Table 34. AbbVie Cardiometabolic Drug Product Offerings
Table 35. AbbVie Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 36. Sanofi Corporate Summary
Table 37. Sanofi Cardiometabolic Drug Product Offerings
Table 38. Sanofi Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 39. InovoBiologic Corporate Summary
Table 40. InovoBiologic Cardiometabolic Drug Product Offerings
Table 41. InovoBiologic Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 42. Carmel Biosciences Corporate Summary
Table 43. Carmel Biosciences Cardiometabolic Drug Product Offerings
Table 44. Carmel Biosciences Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 45. Genfit Corporate Summary
Table 46. Genfit Cardiometabolic Drug Product Offerings
Table 47. Genfit Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 48. Kochi Prefecture Corporate Summary
Table 49. Kochi Prefecture Cardiometabolic Drug Product Offerings
Table 50. Kochi Prefecture Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)
Table 51. Besins Healthcare Corporate Summary
Table 52. Besins Healthcare Cardiometabolic Drug Product Offerings
Table 53. Besins Healthcare Cardiometabolic Drug Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Cardiometabolic Drug Segment by Type in 2021
Figure 2. Cardiometabolic Drug Segment by Application in 2021
Figure 3. Global Cardiometabolic Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cardiometabolic Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cardiometabolic Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cardiometabolic Drug Revenue in 2021
Figure 8. By Type - Global Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 12. US Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 16. Germany Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 17. France Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 24. China Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 28. India Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 30. Brazil Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cardiometabolic Drug Revenue Market Share, 2017-2028
Figure 33. Turkey Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cardiometabolic Drug Revenue, (US$, Mn), 2017-2028
Figure 37. Gilead Sciences Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AbbVie Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sanofi Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. InovoBiologic Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Carmel Biosciences Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Genfit Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kochi Prefecture Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Besins Healthcare Cardiometabolic Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)